On Aug. 16, 2022, UNICEF announced that it had awarded a contract for the first ever supply of a malaria vaccine to GSK with a value of up to USD 170 million[1]. The landmark award will lead to 18 million doses of RTS,S/AS01 (RTS,S) being available over the next three years, potentially saving thousands of lives every year.